These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37947382)

  • 1. An updated patent review of GPR40/ FFAR1 modulators (2020 - present).
    Ren Q; Fan Y; Yang L; Shan M; Shi W; Qian H
    Expert Opin Ther Pat; 2023; 33(9):565-577. PubMed ID: 37947382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.
    Matsuda-Nagasumi K; Takami-Esaki R; Iwachidow K; Yasuhara Y; Tanaka H; Ogi K; Nakata M; Yano T; Hinuma S; Taketomi S; Odaka H; Kaisho Y
    Diabetes Obes Metab; 2013 Jun; 15(6):538-45. PubMed ID: 23331570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans.
    Wagner R; Kaiser G; Gerst F; Christiansen E; Due-Hansen ME; Grundmann M; Machicao F; Peter A; Kostenis E; Ulven T; Fritsche A; Häring HU; Ullrich S
    Diabetes; 2013 Jun; 62(6):2106-11. PubMed ID: 23378609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of a novel free fatty acid receptor 1 (FFAR1) agonist peptide by phage display and machine learning based-amino acid substitution.
    Yoshioka K; Yamashita H; Shimizu K; Shimomura S; Shibata T; Miyazaki JI; Honda H
    Biochem Biophys Res Commun; 2021 Apr; 550():177-183. PubMed ID: 33706101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status.
    Eleazu C; Charles A; Eleazu K; Achi N
    Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates.
    Rady B; Liu J; Huang H; Bakaj I; Qi J; Lee SP; Martin T; Norquay L; Player M; Pocai A
    Front Endocrinol (Lausanne); 2022; 13():1061688. PubMed ID: 36482991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion.
    Panse M; Gerst F; Kaiser G; Teutsch CA; Dölker R; Wagner R; Häring HU; Ullrich S
    Cell Physiol Biochem; 2015; 35(4):1537-45. PubMed ID: 25792236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure.
    Kristinsson H; Bergsten P; Sargsyan E
    Biochim Biophys Acta; 2015 Dec; 1853(12):3248-57. PubMed ID: 26408932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance.
    Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S
    Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
    Zhang X; Macielag MJ
    Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1.
    Tunaru S; Bonnavion R; Brandenburger I; Preussner J; Thomas D; Scholich K; Offermanns S
    Nat Commun; 2018 Jan; 9(1):177. PubMed ID: 29330456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1.
    Kohara K; Obata A; Kimura T; Shimoda M; Moriuchi S; Okauchi S; Hirukawa H; Mune T; Kaku K; Kaneto H
    Endocr J; 2019 Jan; 66(1):43-50. PubMed ID: 30333365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
    Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
    Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.